JP2017506264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506264A5 JP2017506264A5 JP2016570201A JP2016570201A JP2017506264A5 JP 2017506264 A5 JP2017506264 A5 JP 2017506264A5 JP 2016570201 A JP2016570201 A JP 2016570201A JP 2016570201 A JP2016570201 A JP 2016570201A JP 2017506264 A5 JP2017506264 A5 JP 2017506264A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- composition according
- ctla
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000004488 maxillary sinus cancer Diseases 0.000 claims description 2
- 208000019303 maxillary sinus carcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN499/DEL/2014 | 2014-02-21 | ||
| IN499DE2014 | 2014-02-21 | ||
| IN3087/DEL/2014 | 2014-10-29 | ||
| IN3087DE2014 | 2014-10-29 | ||
| PCT/IN2015/000099 WO2015125159A1 (en) | 2014-02-21 | 2015-02-20 | Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016875A Division JP2019077723A (ja) | 2014-02-21 | 2019-02-01 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506264A JP2017506264A (ja) | 2017-03-02 |
| JP2017506264A5 true JP2017506264A5 (enExample) | 2018-01-18 |
| JP6963385B2 JP6963385B2 (ja) | 2021-11-10 |
Family
ID=53055076
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570201A Active JP6963385B2 (ja) | 2014-02-21 | 2015-02-20 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
| JP2019016875A Withdrawn JP2019077723A (ja) | 2014-02-21 | 2019-02-01 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
| JP2021018007A Withdrawn JP2021073296A (ja) | 2014-02-21 | 2021-02-08 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016875A Withdrawn JP2019077723A (ja) | 2014-02-21 | 2019-02-01 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
| JP2021018007A Withdrawn JP2021073296A (ja) | 2014-02-21 | 2021-02-08 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10010587B2 (enExample) |
| EP (2) | EP3134123B1 (enExample) |
| JP (3) | JP6963385B2 (enExample) |
| KR (1) | KR102410090B1 (enExample) |
| CN (1) | CN106132438B (enExample) |
| AU (3) | AU2015220408B2 (enExample) |
| CA (1) | CA2937660A1 (enExample) |
| CY (1) | CY1124226T1 (enExample) |
| DK (1) | DK3134123T3 (enExample) |
| ES (1) | ES2872848T3 (enExample) |
| HR (1) | HRP20210377T1 (enExample) |
| HU (1) | HUE053982T2 (enExample) |
| IL (1) | IL247320B (enExample) |
| LT (1) | LT3134123T (enExample) |
| MX (2) | MX385194B (enExample) |
| PL (1) | PL3134123T3 (enExample) |
| PT (1) | PT3134123T (enExample) |
| RS (1) | RS61661B1 (enExample) |
| SI (1) | SI3134123T1 (enExample) |
| SM (1) | SMT202100191T1 (enExample) |
| WO (1) | WO2015125159A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| FI3077041T3 (fi) | 2013-12-05 | 2024-10-16 | Rfemb Holdings Llc | Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb) |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| PT3134123T (pt) | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| CA2975123A1 (en) | 2015-01-30 | 2016-08-04 | Rfemb Holdings, Llc | Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue |
| CA2991628C (en) | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| KR102722730B1 (ko) | 2015-10-02 | 2024-10-25 | 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 | 인간 증식 및 분화 인자 15 (gdf-15)의 저해제와 면역 체크포인트 차단제를 이용한 병용 요법 |
| EP3356827B1 (en) | 2015-10-02 | 2023-12-06 | Julius-Maximilians-Universität Würzburg | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| WO2017062832A1 (en) * | 2015-10-08 | 2017-04-13 | Nektar Therapeutics | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist |
| CN119185322A (zh) | 2015-11-20 | 2024-12-27 | 生华生物科技股份有限公司 | 用于治疗癌症的四环喹诺酮类似物组合疗法 |
| CA3011460A1 (en) | 2016-01-15 | 2017-07-20 | Rfemb Holdings, Llc | Immunologic treatment of cancer |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| MA44483A (fr) | 2016-03-24 | 2019-01-30 | Millennium Pharm Inc | Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires |
| CA3034266A1 (en) * | 2016-08-19 | 2018-02-22 | Brooklyn Immunotherapeutics Llc | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer |
| CA3043597A1 (en) * | 2016-11-10 | 2018-05-17 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| AU2018207283C1 (en) * | 2017-01-10 | 2024-05-02 | Nektar Therapeutics | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods |
| US11318164B2 (en) | 2017-03-01 | 2022-05-03 | Nektar Therapeutics | Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| EP3628010A4 (en) | 2017-05-02 | 2021-02-17 | Nektar Therapeutics | IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE |
| AU2018271751B2 (en) | 2017-05-25 | 2021-04-01 | Institute For Basic Science | Anti-human interleukin-2 antibodies and uses thereof |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| US12030940B2 (en) | 2017-08-17 | 2024-07-09 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| KR20200084880A (ko) * | 2017-11-06 | 2020-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2019094396A1 (en) * | 2017-11-07 | 2019-05-16 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| BR112020009363A2 (pt) * | 2017-11-13 | 2020-10-27 | Bioxcel Therapeutics, Inc. | métodos e composições para tratar câncer por modificação de múltiplos braços do sistema imunológico |
| KR102777151B1 (ko) | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| EP3752149A4 (en) | 2018-02-15 | 2022-03-02 | Senhwa Biosciences, Inc. | QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| US12565525B2 (en) * | 2018-03-28 | 2026-03-03 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| US20210355223A1 (en) | 2018-11-05 | 2021-11-18 | Pfizer Inc. | Combinations for Treating Cancer |
| US20210386826A1 (en) | 2018-11-05 | 2021-12-16 | Pfizer Inc. | Combination for Treating Cancer |
| MX2021005708A (es) | 2018-11-16 | 2021-09-21 | Bristol Myers Squibb Co | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| CN115362168A (zh) | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
| MX2022008770A (es) | 2020-01-14 | 2022-10-07 | Synthekine Inc | Muteinas de la il2. |
| WO2021242728A1 (en) * | 2020-05-26 | 2021-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab |
| CA3178074A1 (en) | 2020-06-03 | 2021-12-09 | Nina Gunnarsson | Il-2 sequences and uses thereof |
| WO2022098954A1 (en) | 2020-11-06 | 2022-05-12 | Nektar Therapeutics | Tlr agonist compounds and related cancer immunotherapy methods |
| LT4243928T (lt) | 2020-11-10 | 2026-06-10 | Catalym Gmbh | Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui |
| AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
| PT4267105T (pt) | 2020-12-28 | 2025-04-30 | Bristol Myers Squibb Co | Composições de anticorpos e métodos de utilização das mesmas |
| KR20240004403A (ko) * | 2021-03-29 | 2024-01-11 | 오디 쎄라퓨틱스 리미티드 | 단백질-거대분자 접합체 및 이의 사용 방법 |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| WO2022256534A1 (en) * | 2021-06-03 | 2022-12-08 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206265B1 (en) * | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CN101084012A (zh) * | 2004-05-20 | 2007-12-05 | 津莫吉尼蒂克斯公司 | 使用il－21和单克隆抗体疗法治疗癌症的方法 |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| CA2611823C (en) | 2005-06-16 | 2013-07-30 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| US8987281B2 (en) | 2010-11-12 | 2015-03-24 | Endocyte, Inc. | Methods of treating cancer |
| ES2699965T3 (es) * | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
| PT3134123T (pt) | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
-
2015
- 2015-02-20 PT PT157210444T patent/PT3134123T/pt unknown
- 2015-02-20 EP EP15721044.4A patent/EP3134123B1/en not_active Revoked
- 2015-02-20 IL IL247320A patent/IL247320B/en unknown
- 2015-02-20 SM SM20210191T patent/SMT202100191T1/it unknown
- 2015-02-20 JP JP2016570201A patent/JP6963385B2/ja active Active
- 2015-02-20 CN CN201580009152.0A patent/CN106132438B/zh active Active
- 2015-02-20 WO PCT/IN2015/000099 patent/WO2015125159A1/en not_active Ceased
- 2015-02-20 EP EP20217706.9A patent/EP3834838A1/en not_active Withdrawn
- 2015-02-20 DK DK15721044.4T patent/DK3134123T3/da active
- 2015-02-20 US US15/120,214 patent/US10010587B2/en active Active
- 2015-02-20 MX MX2016010870A patent/MX385194B/es unknown
- 2015-02-20 LT LTEP15721044.4T patent/LT3134123T/lt unknown
- 2015-02-20 AU AU2015220408A patent/AU2015220408B2/en active Active
- 2015-02-20 SI SI201531552T patent/SI3134123T1/sl unknown
- 2015-02-20 CA CA2937660A patent/CA2937660A1/en active Pending
- 2015-02-20 HU HUE15721044A patent/HUE053982T2/hu unknown
- 2015-02-20 RS RS20210363A patent/RS61661B1/sr unknown
- 2015-02-20 HR HRP20210377TT patent/HRP20210377T1/hr unknown
- 2015-02-20 KR KR1020167023162A patent/KR102410090B1/ko active Active
- 2015-02-20 ES ES15721044T patent/ES2872848T3/es active Active
- 2015-02-20 PL PL15721044T patent/PL3134123T3/pl unknown
-
2016
- 2016-08-19 MX MX2021009926A patent/MX2021009926A/es unknown
-
2018
- 2018-06-04 US US15/997,487 patent/US10786552B2/en active Active
-
2019
- 2019-02-01 JP JP2019016875A patent/JP2019077723A/ja not_active Withdrawn
-
2020
- 2020-08-04 AU AU2020213296A patent/AU2020213296A1/en not_active Abandoned
- 2020-08-12 US US16/991,936 patent/US20200368321A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021018007A patent/JP2021073296A/ja not_active Withdrawn
- 2021-04-07 CY CY20211100297T patent/CY1124226T1/el unknown
-
2022
- 2022-05-25 AU AU2022203550A patent/AU2022203550A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sternberg et al. | A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| Ghiringhelli et al. | The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy | |
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2017536340A5 (enExample) | ||
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| HK1255039A1 (zh) | 对pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 | |
| MA41038B1 (fr) | Composés d'aminopyridyloxypyrazole | |
| RU2017145558A (ru) | Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака | |
| JP2018508483A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
| JP2017500057A5 (enExample) | ||
| JP2016540042A5 (enExample) | ||
| WO2012177595A9 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
| JP2017537892A5 (enExample) | ||
| WO2011106300A3 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| CN107801379A (zh) | 抗癌剂 | |
| WO2015157629A3 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| WO2016130539A3 (en) | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof | |
| JP2013523843A5 (enExample) | ||
| WO2013023043A3 (en) | Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy | |
| WO2017177217A3 (en) | Chimeric receptors and uses thereof in immune therapy | |
| HK1259083A1 (zh) | 用於治疗系统性肥大细胞增多症的方法和组合物 | |
| WO2013170263A3 (en) | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics |